Alzheimer's Research
To learn more about Alzheimer’s, memory loss and ongoing clinical trials in this area, visit our Alzheimer’s Disease Research page.
Learn MoreThe main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
Participants must have a reliable study partner with whom they have regular contact and who can be contacted during the study
Participants in the United States must be 65 to 80 years old. Participants in Japan must be 55 to 80 years old
Participants must not have been diagnosed with a condition that causes memory or thinking problems such as dementia or early dementia, or a significant disease of the brain
Participants must not have a serious medical condition, such as a neurologic or psychiatric illness, or a history of a serious medical condition, including certain types of cancers
Participants must not have a history of severe drug allergies or hypersensitivity reactions
Participants must not have any allergies to Donanemab or its components
Participants must not have certain health conditions that prevent them from getting an MRI
Participants must not have certain abnormal lab or MRI values at screening
Participants must not have taken certain medicines or had certain treatments
Participant must not be pregnant or can become pregnant during the study (for example, have not had menopause or ovary removal)
To learn more about Alzheimer’s, memory loss and ongoing clinical trials in this area, visit our Alzheimer’s Disease Research page.
Learn MoreTo learn more about neurological disorders and ongoing clinical trials in the area, visit our Neurological Disorders Research page.
A clinical trial helps us learn if a new potential medicine or treatment works and how it works. Clinical trials are also called clinical research studies. To learn more about what to expect when taking part in a clinical trial, visit our Clinical Trial Information page.